• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Remote consultation video
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma Nurse Guides
    • Myeloma health economic model
    • Laboratory Practice
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Emerging treatments

Multiple Myeloma Yields to CD38 Inhibitors.
[No authors listed]. Cancer Discov. 2015 Jan 16. [Epub ahead of print].

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.
Atrash S et al. Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93.

Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
Mangiacavalli S et al. Leuk Lymphoma. 2015 Jan 14:1-2. [Epub ahead of print].

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ et al. Am J Hematol. 2015 Jan;90(1):42-9. doi: 10.1002/ajh.23868.

  • Guidelines
  • Patient Support and Information
  • Medical animations
  • Remote consultation video
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG